Understanding the dose–response is critical for successful drug development. We describe an adaptive design to efficiently learn about the dose–response and the ED95. A dynamic termination rule allows for early discontinuation either for efficacy or futility. The design was deployed in ASTIN, a phase II proof-of-concept trial of the neuroprotectant, neutrophil inhibitory factor (NIF), in acute stroke. We discuss the learning from this trial.
Get full access to this article
View all access options for this article.
References
1.
1. Lesko LJ, Rowland M, Peck CC, Blaschke TF. Optimizing the science of drug devlopment: opportunities for better candidate selection and accelerated evaluation in humans. J Clin Pharmacol2000; 40: 803–814.
2.
2. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Therapeut1997; 61: 275–291.
3.
3. Müller H-G, Schmitt T. Choice of number of doses for maximum likelihood estimation of the ED50 for quantal dose–response data. Biometrics1990; 46: 117–129.
4.
4. Jorgensen HS, Nakayama H, Raaschou HO, Vive-Larsen J, Stoier M, Olsen TS. Outcome and time course of recovery in stroke. The Copenhagen Stroke Study. Archives Physical Medical Rehabilitation, 1995; 76: 399–412.
5.
5. Lees KR, Diener H-C, Asplund K, Krams M. UK 279,276, a neutrophil inhibitory glycoprotein, in acute stroke: tolerability and pharmacokinetics. Stroke2003; 34: 1704–1709.
6.
6. West M, Harrison PJ. Bayesian forecasting and dynamic models, 2nd edition. New York: Springer Verlag, 1997.
7.
7. Berry DA, Müller P, Grieve AP et al. Adaptive Bayesian designs for dose-ranging trials. In Carlin B, Carriquiry A, Gatsonis C et al. eds. Case studies in Bayesian statistics V. New York: Springer Verlag, 2002: 99–181.
8.
8. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo J-M, Ford GA. Acute stroke therapy by inhibition of neutrophils (ASTIN): An adaptive dose–response study of UK-279,276 in acute ischaemic stroke. Stroke2003; 34: 2543–2548.
9.
9. Tamura RN, Faries DE, Andersen JS,Heiligenstein JH. A case study of an adaptive treatment allocation in a clinical trial in the treatment of out-patients with depressive disorder. J Am Statist Assoc89: 768–776.
